Essentra plc has completed its $455m acquisition of Clondalkin SPD, opening up the USA, the world’s largest pharmaceutical and beauty packaging market, to the company.
Essentra plc, headquartered in the UK and listed on the London Stock Exchange’s FTSE 250 market, announced the deal last November and confirmed it had completed following regulatory approval.
The acquisition adds 2,400 people in 24 facilities, including nine in North America as well as in the UK, Ireland, Spain, Poland and the Netherlands, to the company’s existing network.
The acquisition will also broaden the suite and flexibility of services it can offer, complementing its existing portfolio of folding cartons, product literature, labels, foil, tapes and authentication capabilities.
Clondalkin SPD’s customer base includes the leading global pharmaceutical and health & personal care companies and half of its revenues come from its operations in the USA.
Malcolm Waugh, managing director, Health & Personal Care Packaging, said, ‘The combination of Essentra’s existing packaging capabilities with Clondalkin’s Specialist Packaging Division is a great example of our ambition to expand our capabilities in attractive end-markets, both geographically and from a product perspective.
‘Bringing together the knowledge, expertise and skills from our combined network represents a fantastic opportunity to respond even better to our customers’ needs, and I am very excited to be leading the team going forward.’
The resulting scale and breadth of the Health & Personal Care Packaging activities has led to the creation of a separate business unit. This will drive progressive performance and add value through sound strategic thinking with key partners, informed by market and customer trends analysis.
